Article
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d.<i>vs</i>40 mg b.i.d. The X-COVID19 Randomized Clinical Trial
2021-11-21
Abstract excerpt
<h4>Summary</h4> It is uncertain whether higher doses of anticoagulants than recommended for thromboprophylaxis are necessary in COVID-19 patients hospitalized in general wards. This is a multicentre, open-label, randomized trial performed in 9 Italian centres, comparing 40 mg b.i.d. vs 40 mg o.d. enoxaparin in COVID-19 patients, between April 30, 2020 and April 25, 2021. Primary efficacy outcome was in-hospital i...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f678a9f1-5d59-51b6-bef4-9ea00e058a4f
- DOI
- 10.1101/2021.11.17.21266488
